Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease - PubMed (original) (raw)
Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease
JulieAnne G McGregor et al. Clin J Am Soc Nephrol. 2012 Feb.
Abstract
Background and objectives: The optimal course of glucocorticoid therapy in anti-neutrophil cytoplasmic autoantibody (ANCA) disease is unknown. This cohort study evaluates effects of glucocorticoid therapy duration on patient outcomes and adverse events.
Design, setting, participants, & measurements: This study assessed 147 patients diagnosed between January 1, 2000 and January 1, 2009 who were treated with glucocorticoids and cyclophosphamide. Patients with end stage kidney disease at presentation, treatment resistance, or who had died within 6 months were excluded. Patients were divided into three groups: 0, 5, or >5 mg prednisone daily at 6 months after therapy initiation. The latter two groups were combined for assessment of adverse events. Wilcoxon rank sum, Kruskal-Wallis, or Fisher's exact tests were used for between-group comparisons. Time to relapse was evaluated by the Kaplan-Meier method with log-rank test for comparison.
Results: There were no differences between groups in ANCA specificity, serum creatinine, frequency of risk factors for relapse, or length of therapy with immunosuppressants. Length of glucocorticoid therapy had no impact on time to relapse (hazard ratio, 0.69 [95% confidence interval (CI), 0.23-2.02]; 1.01, [95% CI, 0.57-1.81] for the 5-mg and >5-mg groups, respectively), relapse-free survival, end stage kidney disease, or death. Patients receiving glucocorticoids beyond 6 months had significantly higher incidence of infections (0.64 infections per person-year versus 0.39, P<0.0001) and a marginally significant higher frequency of new-onset diabetes mellitus (odds ratio, 2.03; 95% CI, 0.94-4.38).
Conclusions: Glucocorticoid therapy beyond 6 months is associated with a significantly greater risk of infections but not a significantly decreased risk of relapse.
Figures
Figure 1.
Derivation of the Glomerular Disease Collaborative Network Anti-Neutrophil Cytoplasmic Antibody Disease Cohort (GDCN ANCA). *Some patients met more than one exclusion criterion.
Figure 2.
Relapse-free survival for the three groups of patients based on prednisone use at 6 months.
Similar articles
- Glucocorticoid maintenance therapy and severe infectious complications in ANCA-associated vasculitis: a retrospective analysis.
Speer C, Altenmüller-Walther C, Splitthoff J, Nusshag C, Kälble F, Reichel P, Morath C, Zeier M, Bergner R, Schaier M. Speer C, et al. Rheumatol Int. 2021 Feb;41(2):431-438. doi: 10.1007/s00296-020-04752-9. Epub 2020 Nov 22. Rheumatol Int. 2021. PMID: 33222006 Free PMC article. - Evaluation of weekly-reduction regimen of glucocorticoids in combination with cyclophosphamide for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis in Japanese patients.
Matsumoto Y, Sada KE, Otsuka F, Takano M, Toyota N, Sugiyama K, Wakabayashi H, Kawabata T, Makino H. Matsumoto Y, et al. Rheumatol Int. 2012 Oct;32(10):2999-3005. doi: 10.1007/s00296-011-2136-z. Epub 2011 Sep 7. Rheumatol Int. 2012. PMID: 21898055 - Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear.
Walsh M, Casian A, Flossmann O, Westman K, Höglund P, Pusey C, Jayne DR; European Vasculitis Study Group (EUVAS). Walsh M, et al. Kidney Int. 2013 Aug;84(2):397-402. doi: 10.1038/ki.2013.131. Epub 2013 Apr 24. Kidney Int. 2013. PMID: 23615499 Clinical Trial. - Recurrence of anti-neutrophil cytoplasmic antibody vasculitis in the kidney allograft.
Lau D, Summers S, Amos L, Simpson I, Mulley W. Lau D, et al. Nephrology (Carlton). 2012 Apr;17 Suppl 1:16-9. doi: 10.1111/j.1440-1797.2012.01586.x. Nephrology (Carlton). 2012. PMID: 22497649 Review. - Outcome of Kidney Transplant in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Buttigieg J, Henderson L, Kidder D. Buttigieg J, et al. Exp Clin Transplant. 2017 Oct;15(5):509-515. doi: 10.6002/ect.2016.0058. Epub 2016 Oct 20. Exp Clin Transplant. 2017. PMID: 27765007 Review.
Cited by
- Intravenous Methylprednisolone in Induction Therapy for ANCA-Associated Vasculitis: How Low Can We Go?
Oliva-Damaso N, Bomback AS. Oliva-Damaso N, et al. Kidney360. 2023 Sep 1;4(9):e1199-e1200. doi: 10.34067/KID.0000000000000257. Kidney360. 2023. PMID: 37768809 Free PMC article. No abstract available. - The factors predicting development of serious infections in ANCA-associated vasculitis.
Uslu Yurteri E, Sezer S, Torgutalp M, Yayla ME, Sahin Eroglu D, Okatan IE, Kelesoglu Dincer AB, Aydemir Guloksuz EG, Yuksel ML, Turgay TM, Ates A, Kinikli G. Uslu Yurteri E, et al. Sarcoidosis Vasc Diffuse Lung Dis. 2023 Jun 29;40(2):e2023015. doi: 10.36141/svdld.v40i2.13243. Sarcoidosis Vasc Diffuse Lung Dis. 2023. PMID: 37382076 Free PMC article. - Steroid Minimization in Adults with Minimal Change Disease.
Koirala A, Jefferson JA. Koirala A, et al. Glomerular Dis. 2021 Jul 29;1(4):237-249. doi: 10.1159/000517626. eCollection 2021 Oct. Glomerular Dis. 2021. PMID: 36751385 Free PMC article. Review. - [Treatment response and complications of older patients with ANCA(antineutrophil cytoplasmatic antibody)-associated vasculitis].
Schulte-Kemna L, Kühne D, Bettac L, Herrmann H, Ludwig U, Kächele M, Schröppel B. Schulte-Kemna L, et al. Z Gerontol Geriatr. 2023 Dec;56(8):661-666. doi: 10.1007/s00391-022-02145-0. Epub 2022 Dec 19. Z Gerontol Geriatr. 2023. PMID: 36534140 Free PMC article. German. - Thirty years of experience with anti-neutrophil cytoplasmic antibody glomerulonephritis in Charles Nicolle Hospital-Tunisia: a retrospective cohort study.
Hajji M, Barbouch S, Goucha R, Hamida FB, Gorsane I, Abderrahim E. Hajji M, et al. Pan Afr Med J. 2022 Jun 1;42:84. doi: 10.11604/pamj.2022.42.84.27914. eCollection 2022. Pan Afr Med J. 2022. PMID: 36034042 Free PMC article.
References
- Fauci AS, Wolff SM, Johnson JS: Effect of cyclophosphamide upon the immune response in Wegener’s granulomatosis. N Engl J Med 285: 1493–1496, 1971 - PubMed
- Novack SN, Pearson CM: Cyclophosphamide therapy in Wegener’s granulomatosis. N Engl J Med 284: 938–942, 1971 - PubMed
- Nachman PH, Hogan SL, Jennette JC, Falk RJ: Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 7: 33–39, 1996 - PubMed
- Holle JU, Gross WL, Latza U, Nölle B, Ambrosch P, Heller M, Fertmann R, Reinhold-Keller E: Improved outcome in 445 patients with Wegener’s granulomatosis in a German vasculitis center over four decades. Arthritis Rheum 63: 257–266, 2011 - PubMed
- Hogan SL, Falk RJ, Chin H, Cai J, Jennette CE, Jennette JC, Nachman PH: Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 143: 621–631, 2005 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P01 DK058335/DK/NIDDK NIH HHS/United States
- T32 DK007750/DK/NIDDK NIH HHS/United States
- P01DK058335/DK/NIDDK NIH HHS/United States
- T32DK007750/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical